8-K: Pulse Biosciences Announces Third Quarter Results and Key Leadership Appointments

Pulse Biosciences reported its third quarter 2024 financial results and announced the appointment of a new Chief Medical Officer of Electrophysiology, along with a new medical advisor.

Summary

• Pulse Biosciences announced its third quarter 2024 financial results, highlighting progress in its clinical programs and team expansion.
• The company's total GAAP costs and expenses for the quarter were $13.7 million, an increase of $2.4 million compared to the same period last year.
• Non-GAAP costs and expenses were $10.4 million, up $1.2 million year-over-year.
• The GAAP net loss for the quarter was $12.7 million, compared to a $10.6 million loss in the prior year.
• Non-GAAP net loss was $9.4 million, compared to $8.5 million in the prior year.
• Cash and cash equivalents totaled $79.0 million as of September 30, 2024, which includes $60 million from a rights offering.
• The company has the potential to raise an additional $66 million through the exercise of warrants.
• Pulse Biosciences appointed David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology and added Andrea Natale, M.D. as a medical advisor.
• The company is progressing with clinical trials for its nano-PFA technology across three devices, with pivotal trials expected to begin in mid-2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive clinical progress and leadership changes, but also increasing losses. The potential for future capital raises is a positive, but the increased losses are a concern.

Positives

• The company is making significant progress in clinical trials for its nano-PFA technology across multiple devices.
• The appointment of a new Chief Medical Officer and medical advisor strengthens the company's leadership team.
• The company has a strong cash position of $79 million, providing financial stability for ongoing operations and clinical trials.
• The potential to raise an additional $66 million through warrants provides further financial flexibility.
• The company is expanding its clinical trial sites in Europe and the U.S.

Negatives

• The company's GAAP net loss increased to $12.7 million for the quarter, compared to $10.6 million in the prior year.
• Non-GAAP net loss also increased to $9.4 million, compared to $8.5 million in the prior year.
• Total GAAP costs and expenses increased by $2.4 million year-over-year, primarily due to stock-based compensation and other compensation expenses.

Risks

• The company's future success depends on the successful completion of clinical trials and regulatory approvals.
• The company's ability to raise additional capital through the exercise of warrants is not guaranteed.
• The company's financial performance is subject to fluctuations in research and development and general and administrative expenses.
• There are risks associated with the development and commercialization of new medical technologies.

Future Outlook

The company anticipates commencing pivotal clinical trials in the U.S. for each of its three devices in mid-2025 and expects to share select European trial data at medical conferences. They also plan to begin commercial use of the nsPFA Percutaneous Electrode System in the coming quarters.

Management Comments

• Burke T. Barrett, President and Chief Executive Officer, stated that the company made significant progress toward delivering the benefits of nano-PFA to patients and providers.
• Burke T. Barrett also mentioned that the company is building its team and infrastructure to support clinical and regulatory initiatives and anticipated growth.
• Dr. David Kenigsberg, Chief Medical Officer of Electrophysiology, expressed his excitement about the potential of nano-PFA and the 360 catheter.
• Dr. Andrea Natale stated that he is excited to support the Pulse team in the clinical efforts for the 360 catheter.

Industry Context

The announcement reflects the growing interest and development in pulsed field ablation technologies for treating atrial fibrillation and other conditions. The company is positioning itself to be a key player in this emerging field.

Comparison to Industry Standards

• Pulse Biosciences is competing with companies like Medtronic, Boston Scientific, and Johnson & Johnson in the electrophysiology market, all of which are also developing or marketing ablation technologies.
• The company's focus on nano-PFA technology is a differentiator, as it aims to provide a more precise and less invasive treatment option compared to traditional ablation methods.
• The company's clinical trial progress is comparable to other companies in the space, with pivotal trials expected to begin in mid-2025.
• The company's financial results are typical for a development-stage medical device company, with increasing expenses related to clinical trials and product development.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the potential for future capital raises.
• Employees may be impacted by the company's growth and expansion.
• Patients may benefit from the development of new treatment options using nano-PFA technology.
• Healthcare providers may benefit from the availability of new and improved treatment options.

Next Steps

• The company will present clinical data at the American Thyroid Association Conference on October 31, 2024.
• The company expects to commence pivotal clinical trials in mid-2025 for multiple devices.
• The company plans to submit an IDE in mid-2025 to support a pivotal trial for the nano-PFA Cardiac Surgical System.
• The company will continue to expand its clinical trial sites in Europe and the U.S.
• The company will continue to build its team and infrastructure to support clinical and regulatory initiatives.

Key Dates

Keywords

nano-PFA, atrial fibrillation, electrophysiology, clinical trials, medical devices, thyroid nodules, cardiac catheter, FDA approval, medical technology, pulse biosciences